Aldoxorubicin

Summary

Aldoxorubicin (CHEMBL2107818) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including soft tissue sarcoma and small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 18
• Chemistry: 750.7 Da · C37H42N4O13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107818
Name	Aldoxorubicin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9810709
Molecular formula	C37H42N4O13
Molecular weight	750.7
InChIKey	OBMJQRLIQQTJLR-USGQOSEYSA-N

SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O

IUPAC name: N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide

Also known as: Aldoxorubicin, Aldoxorubicina, Aldoxorubicine, Doxo-emch, Doxorubicin-emch, Inno-206, ALDOXORUBICIN

Parent form; salt/anhydrous children: CHEMBL2107827

Patent coverage: 46 distinct patent families (82 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 67 (82%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Replicase polyprotein 1ab.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0DTD1	6.24	IC50	580	nM	CHEMBL_ACT_19964297

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
soft tissue sarcoma	3	MONDO:0018078	EFO:1001968
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
pancreatic ductal adenocarcinoma	2	MONDO:0005184	MONDO:0005184
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	8
PHASE1/PHASE2	4
PHASE1	4
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02049905	PHASE3	COMPLETED	Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
NCT04390399	PHASE2	ACTIVE_NOT_RECRUITING	Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT00472771	PHASE2	WITHDRAWN	INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
NCT01514188	PHASE2	COMPLETED	Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
NCT01580397	PHASE2	COMPLETED	Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
NCT02200757	PHASE2	COMPLETED	Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
NCT03387085	PHASE1/PHASE2	TERMINATED	QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT03387098	PHASE1/PHASE2	TERMINATED	QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03387111	PHASE1/PHASE2	TERMINATED	QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
NCT03554109	PHASE2	WITHDRAWN	QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
NCT03563144	PHASE2	WITHDRAWN	QUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT03574649	PHASE2	WITHDRAWN	QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
NCT03586869	PHASE1/PHASE2	TERMINATED	QUILT-3.080: NANT Pancreatic Cancer Vaccine
NCT01337505	PHASE1	COMPLETED	Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
NCT01673438	PHASE1	COMPLETED	Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
NCT01706835	PHASE1	COMPLETED	Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
NCT02235688	PHASE1	COMPLETED	Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
NCT02570412	Not specified	NO_LONGER_AVAILABLE	Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).